NSNicole Schupf

Nicole Schupf

*This is an algorithmically generated author record based on publicly available information.

Nicole Schupf has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Warren B. Zigman

    New York State Institute for Basic Research in Developmental Disabilities

    11 shared publications
  • Wayne Silverman

    Kennedy Krieger Institute and Johns Hopkins University School of Medicine, Baltimore, MD

    9 shared publications
  • Deborah Pang

    The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, N.Y

    8 shared publications
  • Joseph H. Lee

    Columbia University Medical Center

    7 shared publications
  • Richard Mayeux

    Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, 639 West 1168th Street, New York, NY 10032, USA

    7 shared publications
  • Benjamin Tycko

    The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, N.Y

    5 shared publications

Latest Publications

  • Open Access

    MEF2C Common Genetic Variation Is Associated With Different Aspects of Cognition in Non-Hispanic White and Caribbean Hispanic Non-demented Older Adults

    by Preeti Sunderaraman, Stephanie Cosentino, Nicole Schupf, Jennifer Manly, Yian Gu, Sandra Barral

    Objectives: Myocyte Enhancer Factor 2C (MEF2C) is identified as a candidate gene contributing to the risk of developing Alzheimer’s disease. However, little is known about whether MEF2C plays a role in specific aspects of cognition among older adults. The current study investigated the association of common variants in the MEF2C gene with four cognitive domains including memory, visuospatial functioning, processing speed and language among non-demented individuals.Method: Participants from two ethnic groups, Non-Hispanic White (NHW; n = 537) and Caribbean Hispanic (CH; n = 1,197) from the Washington Heights-Inwood Community Aging Project (WHICAP) study, were included. Genetic association analyses using WHICAP imputed genome-wide data (GWAS) were conducted for the various cognition domains.Results: Single nucleotide polymorphisms (SNP) variants in the MEF2C gene showed nominally significant associations in all cognitive domains but for different SNPs across both the ethnic groups. In NHW participants, the strongest associations were present for memory (rs302484), language (rs619584), processing speed (rs13159808), and visuospatial functioning (several SNPs). In CH, strongest associations were observed for memory (rs34822815), processing speed (rs304141), visuospatial functioning (rs10066711 and rs10038371), and language (rs304153).Discussion: MEF2C variant-cognitive associations shed light on an apparent role for MEF2C in both memory and non-memory aspects of cognition in individuals from NHW and CH ancestries. However, the little overlap in the specific SNP-cognition associations in CH versus NHW highlights the differences in genetic architectural variations among those from different ancestries that should be considered while studying the MEF2C gene.


  • Age and Sex Distributions of Age‐Related Biomarker Values in Healthy Older Adults from the Long Life Family Study

    by Paola Sebastiani, Bharat Thyagarajan, Fangui Sun, Lawrence S. Honig, Nicole Schupf, Stephanie Cosentino, Mary F. Feitosa, Mary Wojczynski, Anne B. Newman, Monty Montano, et al.

    Objectives: To determine reference values for laboratory tests in individuals aged 85 and older. Design: Cross‐sectional cohort study. Setting: International. Participants: Long Life Family Study (LLFS) participants (N~5,000, age: range 25–110, median 67, 45% male). Measurements: Serum biomarkers were selected based on association with aging‐related diseases and included complete blood count, lipids (triglycerides, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, total cholesterol), 25‐hydroxyvitamin D2 and D3, vitamin D epi‐isomer, diabetes mellitus–related biomarkers (adiponectin, insulin, insulin‐like growth factor 1, glucose, glycosylated hemoglobin, soluble receptor for advanced glycation endproduct), kidney disease–related biomarkers (albumin, creatinine, cystatin), endocrine biomarkers (dehydroepiandrosterone, sex‐hormone binding globulin, testosterone), markers of inflammation (interleukin 6, high‐sensitivity C‐reactive protein, N‐terminal pro b‐type natriuretic peptide), ferritin, and transferrin. Results: Of 38 measured biomarkers, 34 were significantly correlated with age. Summary statistics were generated for all biomarkers according to sex and 5‐year age increments from 50 and up after excluding participants with diseases and treatments that were associated with biomarkers. A biomarker data set was also generated that will be useful for other investigators seeking to compare biomarker levels between studies. Conclusion: Levels of several biomarkers change with older age in healthy individuals. The descriptive statistics identified herein will be useful in future studies and, if replicated in additional studies, might also become useful in clinical practice. The availability of the reference data set will facilitate appropriate calibration of biomarkers measured in different laboratories.


  • Open Access

    Genome wide association and linkage analyses identified three loci—4q25, 17q23.2, and 10q11.21—associated with variation in leukocyte telomere length: the Long Life Family Study

    by Joseph H. Lee, Rong Cheng, Lawrence S. Honig, Mary Feitosa, Candace M. Kammerer, Min S. Kang, Nicole Schupf, Shiow J. Lin, Jason L. Sanders, Harold Bae, et al.

    Leukocyte telomere length is believed to measure cellular aging in humans, and short leukocyte telomere length is associated with increased risks of late onset diseases, including cardiovascular disease, dementia, etc. Many studies have shown that leukocyte telomere length is a heritable trait, and several candidate genes have been identified, including TERT, TERC, OBFC1, and CTC1. Unlike most studies that have focused on genetic causes of chronic diseases such as heart disease and diabetes in relation to leukocyte telomere length, the present study examined the genome to identify variants that may contribute to variation in leukocyte telomere length among families with exceptional longevity. From the genome wide association analysis in 4,289 LLFS participants, we identified a novel intergenic SNP rs7680468 located near PAPSS1 and DKK2 on 4q25 (p=4.7E-8). From our linkage analysis, we identified two additional loci with HLOD scores exceeding three, including 4.77 for 17q23.2 and 4.36 for 10q11.21. These two loci harbor a number of novel candidate genes with SNPs, and our gene-wise association analysis identified multiple genes, including DCAF7, POLG2, CEP95, and SMURF2 at 17q23.2; and RASGEF1A, HNRNPF, ANF487, CSTF2T, and PRKG1 at 10q11.21. Among these genes, multiple SNPs were associated with leukocyte telomere length, but the strongest association was observed with one contiguous haplotype in CEP95 and SMURF2. We also show that three previously reported genes – TERC, MYNN, and OBFC1 – were significantly associated with leukocyte telomere length at pempirical smaller than 0.05.


  • Open Access

    COSMIC (Cohort Studies of Memory in an International Consortium): An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups

    by Cosmic, Perminder S Sachdev, Darren M Lipnicki, Nicole A Kochan, John D Crawford, Kenneth Rockwood, Shifu Xiao, Juan Li, Xia Li, Carol Brayne, et al.

    A large number of longitudinal studies of population-based ageing cohorts are in progress internationally, but the insights from these studies into the risk and protective factors for cognitive ageing and conditions like mild cognitive impairment and dementia have been inconsistent. Some of the problems confounding this research can be reduced by harmonising and pooling data across studies. COSMIC (Cohort Studies of Memory in an International Consortium) aims to harmonise data from international cohort studies of cognitive ageing, in order to better understand the determinants of cognitive ageing and neurocognitive disorders. Longitudinal studies of cognitive ageing and dementia with at least 500 individuals aged 60 years or over are eligible and invited to be members of COSMIC. There are currently 17 member studies, from regions that include Asia, Australia, Europe, and North America. A Research Steering Committee has been established, two meetings of study leaders held, and a website developed. The initial attempts at harmonising key variables like neuropsychological test scores are in progress. The challenges of international consortia like COSMIC include efficient communication among members, extended use of resources, and data harmonisation. Successful harmonisation will facilitate projects investigating rates of cognitive decline, risk and protective factors for mild cognitive impairment, and biomarkers of mild cognitive impairment and dementia. Extended implications of COSMIC could include standardised ways of collecting and reporting data, and a rich cognitive ageing database being made available to other researchers. COSMIC could potentially transform our understanding of the epidemiology of cognitive ageing, and have a world-wide impact on promoting successful ageing.


  • Apolipoprotein E and familial longevity

    by Nicole Schupf, Sandra Barral, Thomas Perls, Anne Newman, Kaare Christensen, Bharat Thyagarajan, Michael Province, Winifred K. Rossi, Richard Mayeux


  • Course and etiology of dysexecutive MCI in a community sample

    by Edward D. Huey, Jennifer J. Manly, Ming‐X. Tang, Nicole Schupf, Adam M. Brickman, Masood Manoochehri, Jesse Mez, Charles DeCarli, Davangere P. Devanand, Richard Mayeux

    Background: Amnestic mild cognitive impairment (aMCI) is associated with an elevated risk of progressing to Alzheimer's disease. Much less is known about the course of dysexecutive mild cognitive impairment (dMCI). The goals of this study were to determine how the profile of cognitive deficits differs over time between patients with dMCI and aMCI, and control subjects; if the type of dementia differs between dMCI and aMCI in patients who progress to dementia; and if dMCI is more associated with stroke and white matter hyperintensity on magnetic resonance imaging (MRI) than aMCI.Methods: The authors undertook a prospective evaluation of an inception cohort of 1167 ethnically diverse elders recruited from an urban community‐based sample monitored with clinical and neuropsychological testing for an average of 4.5 years (standard deviation, 0.8 year). A subset of the subjects underwent MRI. We compared four groups of MCI patients: single‐domain amnestic and dysexecutive MCI, and multiple‐domain MCI with and without executive dysfunction.Results: Compared with aMCI, dMCI was less likely to involve other areas of cognition over time and progress to dementia. None of the 33 single‐domain dMCI patients progressed to dementia. The presence of executive dysfunction in multiple‐domain MCI did not increase risk of progression to dementia. Patients with multiple‐domain MCI with executive dysfunction who progressed to dementia were less likely to have an Alzheimer's–type dementia than MCI patients without executive dysfunction. Patients with dMCI were more likely to experience stroke, but not white matter hyperintensity, detected via MRI than patients with aMCI.Conclusions: dMCI appears to follow a different course, and is less associated with Alzheimer's disease and more associated with stroke than aMCI.


  • Open Access

    Variants in CYP17 and CYP19 Cytochrome P450 Genes are Associated with Onset of Alzheimer's Disease in Women with Down Syndrome

    by Constance Chace, Deborah Pang, Catherine Weng, Alexis Temkin, Simon Lax, Wayne Silverman, Warren Zigman, Michel Ferin, Joseph H. Lee, Benjamin Tycko, et al.

    CYP17 and CYP19 are involved in the peripheral synthesis of estrogens, and polymorphisms in CYP17 and CYP19 have been associated with increased risk of estrogen-related disorders. Women with Down syndrome (DS) have early onset and high risk for Alzhe


  • Estrogen Receptor-Beta Variants Are Associated with Increased Risk of Alzheimer’s Disease in Women with Down Syndrome

    by Qi Zhao, Joseph H. Lee, Deborah Pang, Alexis Temkin, Naeun Park, Sarah C. Janicki, Warren B. Zigman, Wayne Silverman, Benjamin Tycko, Nicole Schupf

    Background/Aims: Genetic variants that affect estrogen activity may influence the risk of Alzheimer’s disease (AD). We examined the relation of polymorphisms in the gene for the estrogen receptor-beta (ESR2) to the risk of AD in women with Down syndrome. Methods: Two hundred and forty-nine women with Down syndrome, 31–70 years of age and nondemented at baseline, were followed at 14- to 18-month intervals for 4 years. Women were genotyped for 13 single-nucleotide polymorphisms (SNPs) in the ESR2 gene, and their association with AD incidence was examined. Results: Among postmenopausal women, we found a 2-fold increase in the risk of AD for women carrying 1 or 2 copies of the minor allele at 3 SNPs in introns seven (rs17766755) and six (rs4365213 and rs12435857) and 1 SNP in intron eight (rs4986938) of ESR2. Conclusion: These findings support a role for estrogen and its major brain receptors in modulating susceptibility to AD in women.


  • Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

    by N. Schupf, W.B. Zigman, M.-X. Tang, D. Pang, R. Mayeux, P. Mehta, W. Silverman

    Objective: To examine changes in levels of plasma amyloid-β (Aβ) peptides, Aβ42 and Aβ40, in relation to onset of Alzheimer disease (AD) in adults with Down syndrome (DS). Methods: Plasma Aβ42 and Aβ40 were measured at initial examination and at follow-up in a community-based cohort of 225 adults with DS who did not have dementia at baseline and were assessed for cognitive/functional abilities and health status and followed at 14- to 20-month intervals. We used Cox proportional hazards modeling to estimate the cumulative incidence of AD by Aβ peptide change group (increasing, no change, or decreasing), adjusting for covariates. Results: Sixty-one (27.1%) of the participants developed AD. At follow-up, a decrease in Aβ42 levels, a decrease in the Aβ42/Aβ40 ratio, and an increase in Aβ40 levels were related to conversion to AD. Compared with the group with increasing levels of Aβ42, the likelihood of developing AD was 5 times higher for those whose plasma Aβ42 levels decreased over follow-up (hazard ratio [HR] = 4.9, 95% confidence interval [CI] 2.1–11.4). Decreasing Aβ42/Aβ40 was also strongly related to AD risk (HR = 4.9, 95% CI 1.8–13.2), while decreasing Aβ40 was associated with lower risk (HR = 0.4, 95% CI 0.2–0.9). Conclusions: Among adults with DS, decreasing levels of plasma Aβ42, a decline in the Aβ42/Aβ40 ratio, or increasing levels of Aβ40 may be sensitive indicators of conversion to AD, possibly reflecting compartmentalization of Aβ peptides in the brain.


  • Shorter telomeres may indicate dementia status in older individuals with Down syndrome

    by Edmund C. Jenkins, Lingling Ye, Hong Gu, Samantha A. Ni, Milen Velinov, Deborah Pang, Sharon J. Krinsky-McHale, Warren B. Zigman, Nicole Schupf, Wayne P. Silverman